Focus: Seaport Therapeutics is a Boston-based biotech company focused on neuroscience discovery with a proprietary platform targeting psychiatry and metabolic diseases. The company is early-stage with a lean pipeline in Phase 2 development.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Seaport is a high-risk, high-upside neuro-focused biotech suitable for scientists seeking platform ownership and early-stage equity exposure, but unsuitable for those prioritizing financial stability or near-term commercial milestones.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Seaport Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Seaport Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo